ライフサイエンスコーパス: therapy with

1 Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg

2 72.5% on biologic, targeted, or immune-based therapies) with 148,138 person-years of follow-up.

3 77 088 participants from 25 trials of statin therapy with 20 962 major vascular events were included,

4 270 participants from 24 trials of nonstatin therapy with 25 218 major vascular events and 177 088 pa

5 s are prescribed with chemo and/or radiation therapies, with 5-year relative survival rates of just 1

6 ntrol asthma were defined as requiring daily therapy with 500 mug or more of fluticasone propionate (

7 80 years were randomly assigned to induction therapy with 6 or 8 cycles of R-CHOP-14 with (RR-CHOP-14

8 Patients received 30 courses of maintenance therapy with 6-mercaptopurine, vincristine, methotrexate

9 randomly assigned (1:1) to receive standard therapy with 7-14 days of intravenous amphotericin B (0.

10 arian and pancreatic cancer for follow-up to therapy with (90)Y-FAPI-46.

11 his review, we discuss the evolution of cell therapies with a focus on stem cell advantages, as well

12 The range of cancer therapies with a vascular toxicity profile and the clini

13 Combining standard therapy with a beta-lactam antibiotic has been associate

14 These observations suggest that combination therapy with a cystine-depleting drug such as cysteamine

15 In simulations, even a low potency therapy with a drug which reduces the replication rate o

16 blation is increasingly used as a first-line therapy with a high acute success rate, but recurrence d

17 index identifies patients with a response to therapy with a high level of accuracy.

18 ict severe outcome and the need for anti-TNF therapy with a high level of precision.

19 that acalabrutinib is active as single-agent therapy with a manageable safety profile in patients wit

20 The combination of the optimized NT therapy with a moderate antibiotic treatment results in

21 s in whom previous first-line antiretroviral therapy with a non-nucleoside reverse transcriptase inhi

22 e findings show that combining an epigenetic therapy with a noncanonical WNT signaling pathway inhibi

23 adjunctive BUP/SAM 2 mg/2 mg combination, a therapy with a novel opioidergic mechanism of action, as

24 bowel syndrome has been shown to respond to therapy with a poorly absorbed antibiotic, the role of S

25 Children not receiving preventive therapy with a positive result for tuberculosis infectio

26 Fixed-duration therapy with a treatment-free remission is a particularl

27 until better data are available, second-line therapy with a tyrosine kinase inhibitor may be recommen

28 ignal a new class of factor VIII replacement therapy with a weekly treatment interval.

29 n high-intensity or maximum-tolerated statin therapy, with a baseline low-density lipoprotein cholest

30 with HIV-1 who were naive to antiretroviral therapy, with a plasma HIV-1 RNA concentration of 1000 c

31 espond most highly with clinical response to therapy, with a reciprocal decrease in cell-cycle and WN

32 Gene therapy with AAV5-hFVIII-SQ vector in participants with

33 The observation that dual antiplatelet therapy with acetylsalicylic acid and clopidogrel was as

34 genetics have facilitated the development of therapies with actionable mutations.

35 Of 30 patients completing DAA therapy with active illicit opioid use at intake, 14 (46

36 Outpatient parenteral antimicrobial therapy with addiction treatment may be feasible and saf

37 angiotensin receptor blocker as foundational therapy, with addition of a mineralocorticoid receptor a

38 Gene therapy with adeno-associated virus (AAV) vectors has de

39 s studies have shown a benefit of concurrent therapies with ADT in both low- and high-volume metastat

40 ude to the supplementation of antiretroviral therapy with ALOX5 antagonists to rescue patients with H

41 With renewed interest in therapy with alpha-particle emitters, and their potentia

42 A 2-day course of antibiotic therapy with amoxicillin-clavulanate in patients receivi

43 Gene therapy with an adeno-associated vector (AAV) serotype 8

44 Long-term therapy with an antibody targeting interleukin-1beta blo

45 s may provide a promising new antithrombotic therapy with an improved benefit to bleeding risk profil

46 ot respond to antiosteoporosis pharmacologic therapy with an improvement in BMD, or who have an incid

47 Immune checkpoint inhibitors are one such therapy with an increasing number of case and cohort rep

48 ge, 65 years; median of three prior lines of therapy) with an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZ

49 who had relapsed after at least one line of therapy, with an Eastern Cooperative Oncology Group perf

50 o had received one or more previous lines of therapy, with an Eastern Cooperative Oncology Group perf

51 eight sessions of individual problem-solving therapy, with an extra two to four sessions if needed) p

52 or failed Bruton's tyrosine kinase inhibitor therapy, with an overall response rate of 93% and an exp

53 ients were 38% and 50% after CD19 CAR T-cell therapy, with and without concurrent ibrutinib, respecti

54 6 proteins was significantly lower following therapy with AngII inhibitors (P < 0.05).

55 The comparative efficacy of pharmacological therapy with angiotensin receptor-neprilysin inhibitors

56 Immune checkpoint therapy with anti-CTLA-4 and anti-PD-1/PD-L1 has revolut

57 Combination therapy with anti-PD-1 antibody further accelerates the

58 e feasible the development and testing of co-therapies with antibiotics that would increase its antim

59 Therapy with antineoplastic agents that inhibit EGFR and

60 HIV-1 infection requires lifelong therapy with antiretroviral drugs due to the existence o

61 undergo prophylactic negative pressure wound therapy, with application of the negative pressure devic

62 The optimal duration of extended therapy with aromatase inhibitors in patients with postm

63 nosed with breast cancer initiating hormonal therapy with aromatase inhibitors or tamoxifen between A

64 h to mild asthma has long relied on reliever therapy with as-needed short-acting beta-agonists (SABAs

65 Dual antiplatelet therapy with aspirin and a P2Y(12) inhibitor has been sh

66 Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recur

67 Gene therapy with autologous HSCs modified to express B-globi

68 n from 15 human tumors show that combination therapy with AZD2014 and dasatinib is more effective at

69 clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cell activating

70 on (alloHSCT) is the only available curative therapy, with benefits derived from the antigenic dispar

71 Early diagnosis and initiation of antibiotic therapy with benzylpenicillin and clindamycin as seen in

72 Here, we combined ATT therapy with bergenin and found that this combination re

73 Extended therapy with biannual rituximab infusions over 18 months

74 Ts reported the outcomes of PSP modification therapy with bilaminar techniques, whereas 7 involved th

75 biomarkers for risk stratification to align therapy with biological risk.

76 ry ECD have benefitted from highly effective therapy with BRAF and MEK inhibitors.

77 a have shown that anti-inflammatory reliever therapy with budesonide-formoterol, given on an as-neede

78 ombining outpatient parenteral antimicrobial therapy with buprenorphine treatment had similar clinica

79 nale for clinical development of combination therapy with BYL719 and LEE011 for treatment of metastat

80 CI 1.4 to 746, P = 0.03) and need for oxygen therapy with C4d (11.7, 1.1 to 130, P = 0.045).

81 Anti-inflammatory therapy with canakinumab significantly reduced the total

82 review preclinical and clinical combination therapy with CAR T cells and CPB agents, with a focus on

83 ears of age, receiving stable antiretroviral therapy with CD4+ T-cell count >100 cells/mm3, and with

84 Yet, combination therapy with CD40 agonist and Flt3 ligand restores cDC1

85 included uveal or mucosal melanoma, previous therapy with checkpoint inhibitors, and any previous imm

86 and developing blocking antibody-combination therapy with chemotherapies or radiotherapy.

87 Chemophototherapy (CPT) merges photodynamic therapy with chemotherapy and can substantially enhance

88 We examined whether further therapy with ciprofloxacin for incompletely resolved COP

89 axel, followed by concomitant chemoradiation therapy with cisplatin, docetaxel, and 45Gy.

90 ) and globus pallidus interna, is a surgical therapy with class 1 evidence for Parkinson's disease (P

91 Therapy with Clostridiales species impacted by dysbiosis

92 rarchically dictated by the efficacy of each therapy with complete or partial independence from the t

93 CD19 CAR T-cell therapy with concurrent ibrutinib was well tolerated; 13

94 onal and randomised studies comparing statin therapy with control (placebo or no treatment) in patien

95 ing prolonged intermittent renal replacement therapy with cooler dialysate experienced significantly

96 are refractory to traditional antirejection therapy with corticosteroids and polyclonal antilymphocy

97 Three and 120 +/- 12 months after therapy with CTG, significantly better root coverage was

98 can bridge to more definitive consolidation therapy with curative intent.

99 his study investigated if blood purification therapy with CytoSorb (CS) porous polymer beads could im

100 as a prerequisite to personalize combination therapies with cytotoxic drugs and inhibitors of signal

101 examined the efficacy of augmenting behavior therapy with D-cycloserine (DCS) to reduce tic severity

102 ized Evaluation of Long-Term Anticoagulation Therapy With Dabigatran Etexilate) (n=11 955 in derivati

103 0E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a lo

104 e regimens or combination BRAF/MEK inhibitor therapy with dabrafenib/trametinib, encorafenib/binimeti

105 he original KPC model and tested combination therapy with DAC followed by immune checkpoint inhibitor

106 rtant to enhance the efficacy of combination therapy with DAC plus ICI.

107 se registry who had been given high-efficacy therapy, with data collected between Jan 1, 1975, and Ap

108 of Blood, Dalton et al show that epigenetic therapy with decitabine can upregulate immunogenic Epste

109 cell sheet technology as a breakthrough cell therapy with demonstrated therapeutic success across ind

110 d optimize the outcomes of tooth replacement therapy with dental implants in this specific anatomic l

111 drugs have been a major hurdle in designing therapies with desired efficacy and acceptable toxicity.

112 nts chronically infected with HCV undergoing therapy with direct-acting antivirals.

113 However, a small previous trial of such therapy with dolutegravir in healthy, HIV-negative adult

114 vir plus rilpivirine was noninferior to oral therapy with dolutegravir-abacavir-lamivudine with regar

115 were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine.

116 [IQR 7-13]), 36 of whom received combination therapy with dose escalation, with a median follow-up of

117 yrA genes for patients undergoing sequential therapy with doxycycline-moxifloxacin (201 patients, inc

118 Combination therapy with drugs able to safely induce NQO1 in neurons

119 ar period suggest an unmet need for glaucoma therapies with durable and predictable actions.

120 = 36), or both (TL; N = 58) as HER2-targeted therapy, with each participant given one cycle of this d

121 The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with

122 n Tanzania was prospectively observed during therapy with either FLC monotherapy or in combination wi

123 mpared safety and efficacy of antiretroviral therapy with either raltegravir or efavirenz in late pre

124 use of permuted blocks to receive induction therapy with either the VRd regimen or the KRd regimen f

125 HIV-1-infected men on stable antiretroviral therapy with elvitegravir, cobicistat, emtricitabine (E/

126 was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of c

127 al new target for monotherapy or combination therapy with established chemotherapeutics to improve tr

128 Other therapies with evidence of effectiveness include proton

129 can be a suitable candidate for combination therapy with existing chemotherapeutic drugs.

130 mal therapy duration and a need for targeted therapies with fewer adverse effects.

131 ore whether the efficacy of a platinum-based therapy with fluorouracil, leucovorin, and oxaliplatin (

132 p) or to receive continuous high-flow oxygen therapy with frequency of suctioning being the indicator

133 ical trials have shown the benefit of double therapy with full-dose novel oral anticoagulants and P2Y

134 efore and 7-9 d after the start of endocrine therapy with fulvestrant.

135 In previous studies, autologous gene therapy with gamma-retroviral vectors failed to reconsti

136 nued LET prophylaxis and received preemptive therapy with ganciclovir.

137 Adoptive cell therapy with genetically modified T cells has generated

138 ucted a randomized trial to compare physical therapy with glucocorticoid injection in the primary car

139 (18)F-FGln study 4-13 wk after initiation of therapy with glutaminase, dual TORC1/2, or programmed de

140 ts Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) has demonstrated that the Hear

141 n day 28 samples, reported responders to CLL therapy with high accuracy.

142 Finally, postsymptomatic therapy with high-dose AAV9 also significantly extended

143 We compared second-line therapy with high-dose chemotherapy and autologous stem

144 We analyzed the association of early NAI therapy with hospital lengths of stay (LOS) and in-hospi

145 ia caused by TBI could be alleviated by cell therapy with human bone marrow mesenchymal stromal cells

146 In gene therapy with human hematopoietic stem and progenitor cel

147 Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV

148 ransplants, 13 (76%) had previously received therapy with hypomethylating agents, and ten (59%) had r

149 es, including in those who have had previous therapy with hypomethylating agents.

150 Salvage therapy with ibrutinib after VenR achieved high response

151 ere randomly assigned up front for induction therapy with idarubicin, cytarabine, etoposide, and all-

152 oral antidiabetic drugs, initial injectable therapy with IDegLira resulted in fewer patients reachin

153 afety of biologic monotherapy vs combination therapy with immunomodulators, (3) comparative efficacy

154 elop treatment regimens combining epigenetic therapies with immunotherapies.

155 rationales for combining telomere-targeting therapy with immunotherapy.

156 csMHCII correlated with response to anti-PD1 therapy, with immunotherapy-sensitive CMT167 cells being

157 enopausal patients (2.8 years after adjuvant therapy) with impaired peak oxygen consumption (VO(2)pea

158 onses are needed to design biomaterial-based therapies with improved outcomes in the setting of aging

159 form for the development of controllable CAR therapies with improved tumor specificity.

160 tandardized off-the-shelf engineered NK cell therapy with improved ADCC properties to treat malignanc

161 synergistic effects due to sequencing of the therapies with in vitro imaging and mathematical modelin

162 ationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patien

163 Some studies have associated antiretroviral therapy with increased risk of myocardial infarction and

164 extraction or revision, long-term antibiotic therapy with infection recurrence, or death, within 12 m

165 itional recommendation for the use of triple therapy with inhaled corticosteroids (ICS)/LABA/LAMA ove

166 Insulin pump therapy with integrated CGM and a suspend-before-low fea

167 sess the safety and efficacy of insulin pump therapy with integrated continuous glucose monitoring (C

168 This suggests that prefacing adjuvant therapy with integrin inhibitors is a viable clinical st

169 Rescue therapy with intraportal MMP inhibitor, given after isch

170 Participants underwent chelation therapy with intravenous CaNa(2)EDTA for 2 days followed

171 ial clinical benefits of metastasis-directed therapy with ionizing radiation (primarily stereotactic

172 Adjuvant therapy with ipi3 benefits survival versus HDI; for the

173 In this study, we compared dual therapy with IV metronidazole and vancomycin vs vancomyc

174 Dual therapy with IV metronidazole and vancomycin was common

175 ed corticosteroids (ICS)/LABA/LAMA over dual therapy with LABA/LAMA in patients with COPD and dyspnea

176 as, benefit from advanced treatments such as therapy with levodopa-carbidopa enteral suspension or de

177 CC who are eligible for potentially curative therapy with liver resection or ablation should defer DA

178 as well as integration of effective systemic therapies with localised interventions, might achieve be

179 Therapy with long-acting cabotegravir plus rilpivirine w

180 Therapy with low-molecular-weight heparin, vitamin K ant

181 cystectomy and urinary diversion or trimodal therapy with maximal endoscopic resection, radiosensitiz

182 arrhythmia, and seven of the eight continued therapy with medical management.

183 drug to elicit renoprotective effects beyond therapy with metformin, ramipril, and empagliflozin (MRE

184 e demonstrated that long-term opioid agonist therapy with methadone and buprenorphine have great effi

185 To evaluate if a combination therapy with micropulse diode laser (MPL) shows non-infe

186 Single-drug therapies with monoclonal antibodies against programmed

187 e risk factors (eg, access to antiretroviral therapy with more benign cardiovascular disease side eff

188 st cancer who have disease progression after therapy with multiple HER2-targeted agents have limited

189 After 5 years' therapy with NA, 27% and 14% had detectable HBcrAg and H

190 Pioneered by the Mayo Clinic, multimodal therapy with neoadjuvant chemoradiotherapy and orthotopi

191 f Pediatric MS Centers, who received initial therapy with newer (fingolimod, dimethyl fumarate, terif

192 ioid EOC should be offered PARPi maintenance therapy with niraparib.

193 tients undergoing long-term and/or high-dose therapy with nitrogen-containing bisphosphonates, a RANK

194 s antibody for prophylaxis and post-exposure therapy with NiV- and HeV-infected individuals.

195 Adjuvant therapy with nivolumab alone or in combination with ipil

196 External validation was performed in four therapies, with no significant difference in the bootstr

197 mutations led to the development of targeted therapies with non-small cell lung cancer (NSCLC) being

198 Several studies demonstrated that antiviral therapy with NUCs could reduce the risk of HCC recurrenc

199 rengthening the rationale behind combination therapy with oncolytic viruses.

200 obinopathies require lifelong iron chelation therapy with one of the three iron chelators (deferipron

201 d controls only received standard endoscopic therapies with only CBD stenting (group A).

202 fy "qualified donors" for convalescent serum therapy with only one fixed dilution factor (200 x).

203 respond to commercially available antiviral therapies, with or without demonstrating genotypic mutat

204 Cell-based therapies, with or without genetic modification ex vivo,

205 3-ITD acute myeloid leukaemia after standard therapy with or without allogeneic haemopoietic stem-cel

206 essed efficacy of retreatment with anti-PD-1 therapy with or without ipilimumab in relapsing patients

207 igature and puncture (CLP) surgery and fluid therapy with or without NButGT.

208 ease, and were on optimal anticholinesterase therapy with or without oral corticosteroids.

209 on, leading to a better response to anti-PD1 therapy with or without radiotherapy.

210 Extending therapy with oral antibiotics had superior infection-fre

211 ss improved delivery methods and combination therapies with other antiviral drugs.

212 Initial therapies with other azoles were excluded.

213 mbining the current generation of epigenetic therapies with other classes of agents and the developme

214 to normal organs was low, making combination therapy with other anticancer therapies feasible.

215 Combination therapy with Ox/Cy and anti-PD-L1 synergistically improv

216 with metronidazole, followed by eradication therapy with paromomycin.

217 se responses vary depending on antimicrobial therapy, with particular interest in whether the superio

218 eurologist preparedness to discuss stem cell therapies with patients and an alarming list of unreport

219 "Switch maintenance" therapy with PD-1 blockade at the time of chemotherapy c

220 immune activation early after initiation of therapy with PD1-blocking antibodies and predicts a clin

221 rdioprotective and suggest that cardiac gene therapy with PDE4B might constitute a new promising appr

222 eyes, anti-VEGF monotherapy and combination therapy with PDT yielded comparable outcomes as those of

223 adults with metastatic melanoma who started therapy with pembrolizumab, nivolumab, or nivolumab/ipil

224 Dual HER2-targeted therapy with pertuzumab plus trastuzumab is well tolerat

225 treatment, <60% of the cohort had induction therapy with polyclonal or monoclonal antibodies, 28% di

226 int blockade represent a novel combinatorial therapy with potential efficacy for this lethal disease.

227 table theranostic scaffold for dosimetry and therapy with potentially broad applicability in pediatri

228 n novel perspectives for combining endocrine therapies with PRMT1 inhibitors in ERalpha-positive tumo

229 Because it is known that several ADPKD therapies with promising outcomes in animal models faile

230 ues are currently being explored in targeted therapies with promising results in preclinical and clin

231 endoscopic myotomy (POEM) is a less invasive therapy with promising early study results.

232 Combination therapy with pyridostigmine and salbutamol counteracted

233 Both arms included induction therapy with rabbit ATG, mycophenolate sodium, or mycoph

234 in current or former smokers, whereas cancer therapy with radiation, platinum and topoisomerase II in

235 ith muscle-invasive disease, more aggressive therapy with radical cystectomy and urinary diversion or

236 Conclusion: Therapy with radiolabeled pentixather appears to be well

237 y for solid tumours, by combining CAR T-cell therapy with radiotherapy through the use of careful mon

238 inical gene therapy.IMPORTANCE Clinical gene therapy with recombinant AAV vectors has largely relied

239 , and might provide an entry point for novel therapies with reduced side effects.

240 Febuxostat is non-inferior to allopurinol therapy with respect to the primary cardiovascular endpo

241 ximab-based regimens were the most effective therapies with, respectively, 53% and 52% of partial or

242 imab resistance of OSCC and that combination therapy with resveratrol may provide an attractive means

243 magnetic navigation for ablation or medical therapy with riociguat (MED group; n = 25).

244 cruited after prostatectomy and/or radiation therapy with rising prostate-specific antigen level (med

245 tent associations of antiviral therapy vs no therapy with risk of hepatocellular carcinoma.

246 and 1192 (59.5%) used proton pump inhibitor therapy, with risk factors for the combined outcome bein

247 e patient was treated with immunosuppressive therapies, with rituximab demonstrating the most robust

248 Gene therapy with sCX3CL1 is a promising mutation-independent

249 s may help us understand the actions of drug therapies with selective effects on one population over

250 AML treatment relies primarily on untargeted therapies with severe side effects that limit patient el

251 indicate that selection of active comparator therapies with similar indications and use patterns enha

252 Targeted therapy with small molecules directed at essential survi

253 Combination therapy with small-molecule inhibitors of AKT and HER2 w

254 we did not find evidence that monoscavenger therapy with sodium or glycerol phenylbutyrate was super

255 Following first-line therapy with sorafenib or lenvatinib, second-line therap

256 rgeting parasite-produced MIF as combination therapy with standard antibiotics to reduce disease seve

257 roves upon current intermittent preventative therapy with sulphadoxine-pyrimethamine (IPTp-SP).

258 on may be a useful adjuvant antiangiogenesis therapy with sunitinib.

259 iency virus (HIV) who were on antiretroviral therapy with suppressed HIV viremia and high CD4 T cell

260 inflammatory cytokines following delivery of therapy, with symptoms ranging from mild fever to life-t

261 While therapy with T cells engineered with a chimeric antigen

262 fficacy, and treatment window of reperfusion therapy with t-PA by limiting hemorrhagic transformation

263 epressants might be compensated by combining therapies with targeted treatment as an optimized approa

264 tive at nanomolar concentrations, complement therapy with temozolomide, and synergize strongly with e

265 hout, patients crossed over to the alternate therapy with the above protocol repeated.

266 combining the immense potential of DNA gene-therapy with the absence of genome integration-associate

267 ssion, SRS can be recommended as the primary therapy with the advantage of low morbidity and satisfac

268 ation anti-HER2 therapy, as well as adjuvant therapy with the anti-HER2 antibody-drug conjugate T-DM1

269 Combination therapy with the CDK7/super-enhancer inhibitor THZ1 and

270 in vitro and in vivo efficacy of combination therapy with the dual mTORC1/2 inhibitor AZD2014 and the

271 tment-naive phakic eyes who had DME, primary therapy with the intravitreal dexamethasone implant PRN

272 stance was overcome by combining ER-directed therapy with the irreversible HER2 kinase inhibitor nera

273 therapy followed by risk-adapted maintenance therapy with the longest follow-up and important informa

274 Thus, therapy with the new CD19-BBz(86) CAR T cells produces a

275 t a rapidly emerging form of adoptive T-cell therapy with the potential to overcome safety and antige

276 ic stem cell-engineered iNKT (HSC-iNKT) cell therapy with the potential to provide therapeutic levels

277 rcise represents a viable, nonpharmaceutical therapy with the potential to reverse and enhance the im

278 C1 are few, and classical enzyme replacement therapy with the recombinant protein is not possible as

279 asive tumors that do not respond to adjuvant therapy with the standard-of-care immunotherapy, bacille

280 its declined over time regardless of initial therapy, with the greatest decrease among the untreated

281 emerged as a promising class of nucleic acid therapy, with the potential to induce protein production

282 Therapy with these agents can be continued throughout pr

283 tablished EBV-PTLD, who had failed rituximab therapy, with third-party EBV-CTLs.

284 g the index procedure and during maintenance therapy with ticagrelor or prasugrel.

285 g man who developed CSCR following prolonged therapy with topical Minoxidil solution and was treated

286 ogressed after at least one previous line of therapy with trastuzumab plus chemotherapy in the locall

287 Maintenance therapy with trebananib or placebo continued for up to 1

288 poisons can be enhanced through combination therapy with ubiquitin-activating enzyme inhibitors or b

289 andomized to a 36-week period of maintenance therapy with upadacitinib.

290 Injection therapy with urethral bulking agents or stem cell formul

291 ong patients who had a response to induction therapy with ustekinumab and underwent a second randomiz

292 refractory CD requiring monoclonal antibody therapy with ustekinumab.

293 ylococcal beta-lactam to standard antibiotic therapy with vancomycin or daptomycin did not result in

294 The addition of atezolizumab to targeted therapy with vemurafenib and cobimetinib was safe and to

295 Photodynamic therapy with verteporfin is an effective outpatient meth

296 egulatory microenvironment and combinatorial therapies with virotherapy, such as checkpoint inhibitor

297 ad, dietary iron restriction and antioxidant therapy with vitamin E prevented liver disease.

298 insensitive CAR T cells enable combinatorial therapy with VSVmIFNbeta.

299 uals on long-term combination antiretroviral therapy with well controlled HIV.

300 there may be novel approaches and potential therapies with wider application to this and other forms